SHARP co-principal investigator, Dr Martin Landray said that SHARP provides reassuring evidence about the safety of the ezetimibe and simvastatin combination: "There was no evidence of any serious adverse effects and, in particular, no support for earlier concerns that ezetimibe might cause cancer.
The results were presented today during Renal Week, the American Society of Nephrology's annual meeting, by Professor Colin Baigent, F.F.P.H., F.R.C.P., and Dr. Martin Landray, Ph.D., F.R.C.P., the principal investigators of SHARP, from the Oxford University Clinical Trial Service Unit (CTSU), Oxford, England.
Dr Martin Landray, an epidemiologist at Oxford University, says that one reason for a knowledge gap between the sexes is that drug trials and medical research into heart conditions still struggle to include as many women as men.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.